Bli medlem
Bli medlem

Du är här

2016-10-13

Minerva Neurosciences Announces Acceptance of Presentations of Clinical Data With MIN-101 and MIN-117 at American College of Neuropsychopharmacology Annual Meet

Minerva Neurosciences, Inc.
Press release

Minerva Neurosciences Announces Acceptance of Presentations of Clinical Data
With MIN-101 and MIN-117 at American College of Neuropsychopharmacology Annual
Meeting

MIN-101 to be highlighted in oral presentation

WALTHAM, Mass., 2016-10-13 14:30 CEST (GLOBE NEWSWIRE) --
Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical
company focused on the development of therapies to treat central nervous system
(CNS) disorders, today announced the acceptance of four abstracts for
presentation at the 55th Annual Meeting of the American College of
Neuropsychopharmacology (ACNP), December 4-8, 2016, at the Diplomat Hotel in
Hollywood, Florida.

Highlighting these is the abstract, “Efficacy and Safety of MIN-101: A New Drug
for the Treatment of Negative Symptoms in Schizophrenia,” selected for both an
oral “Hot Topic” presentation and a poster session. These presentations will
include clinical data, including recent analyses, from the core phase of the
Company’s Phase IIb trial with MIN-101 as monotherapy for unmet needs in
patients suffering from schizophrenia, particularly negative symptoms.

“We are delighted that the ACNP has selected findings from our Phase IIb
clinical trial with MIN-101 to be featured in an oral presentation at their
annual meeting, one of the most prestigious conferences in the field of
psychiatric disorders,” said Dr. Remy Luthringer, president and chief executive
officer of Minerva.

The following abstracts related to MIN-101 and MIN-117 have been accepted and
posted on the ACNP web site at www.acnp.org. The schedule for these
presentations is as follows:

1. Abstract title: “Efficacy and Safety of MIN-101: A New Drug for the
Treatment of Negative Symptoms in Schizophrenia”
Session: Hot Topics
Date and Time: December 4, 2016, 2:30 p.m. – 5:30 p.m.; MIN-101
presentation scheduled from 3:45 p.m. – 4:00 p.m.
Location: Regency 1-2
2. Abstract title: “Efficacy and Safety of MIN-101: A New Drug for the
Treatment of Negative Symptoms in Schizophrenia”
Session: Poster Session I, Poster Board M218
Date and Time: December 5, 2016, 5:30 p.m. – 7:30 p.m.
Location: Great Hall 1-4
3. Abstract title: “MIN-101 Improves Sleep in Patients Suffering From
Schizophrenia: A Randomized, Placebo-Controlled, Double Blind Study”
Session: Poster Session III, Poster Board W192
Date and Time: December 7, 2016, 5:30 p.m. – 7:30 p.m.
Location: Great Hall 1-4
4. Abstract title: “Effect of MIN-101 on Cognition in Schizophrenia Patients
With Predominant Negative Symptoms: A 12-Week Randomized, Double Blind,
Placebo-Controlled Trial”
Session: Poster Session II, Poster Board T167
Date and Time: December 6, 2016, 5:30 p.m. – 7:30 p.m.
Location: Great Hall 1-4
5. Abstract title: “A Randomized, Double-Blind, Parallel-Group, Placebo- and
Active-Controlled Study to Evaluate the Efficacy and Safety of MIN-117 in
Patients With Major Depressive Disorder”
Session: Poster Session II, Poster Board T132
Date and Time: December 6, 2016, 5:30 p.m. – 7:30 p.m.
Location: Great Hall 1-4

MIN-101

MIN-101 is a drug candidate with equipotent affinities for sigma 2 and
5?hydroxytryptamine-2A (5-HT2A) and lower affinity at ?1-adrenergic receptors.
MIN-101 has no direct dopaminergic post-synaptic blocking effects, known to be
involved in some side effects like extrapyramidal symptoms, sedation, prolactin
increases and weight gain.

MIN-117

MIN-117 is an antidepressant drug candidate with a differentiated mechanism of
action targeting adrenergic alpha 1a, alpha 1b, 5-HT1A, 5-HT2A receptors,
serotonin and the dopamine transporters.

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company
focused on the development and commercialization of a portfolio of products to
treat CNS diseases. Minerva’s proprietary compounds include: MIN-101, which
recently completed a Phase IIb clinical trial for schizophrenia; MIN-117, which
recently completed a Phase IIa clinical trial development for MDD; MIN-202
(JNJ-42847922), which recently completed Phase IIa and Phase Ib clinical trials
for insomnia and MDD, respectively; and MIN-301, in pre-clinical development
for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global
Market under the symbol “NERV.” For more information, please visit
www.minervaneurosciences.com.

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements which are subject to the
safe harbor provisions of the Private Securities Litigation Reform Act of 1995,
as amended. Forward-looking statements are statements that are not historical
facts, reflect management’s expectations as of the date of this press release,
and involve certain risks and uncertainties. Forward-looking statements
include statements herein with respect to the timing and results of future
clinical milestones with MIN-101 and MIN-117; the clinical and therapeutic
potential of MIN-101 and MIN-117; our ability to successfully develop and
commercialize MIN-101 and MIN-117; and management’s ability to successfully
achieve its goals. These forward-looking statements are based on our current
expectations and may differ materially from actual results due to a variety of
factors including, without limitation, whether MIN-101 and MIN-117 will advance
further in the clinical trials process and whether and when, if at all, they
will receive final approval from the U.S. Food and Drug Administration or
equivalent foreign regulatory agencies and for which indications; whether the
results of future clinical trials of MIN-101 and MIN-117, if any, will be
consistent with the results of past clinical trials; whether MIN-101 and
MIN-117 will be successfully marketed if approved; whether our therapeutic
product discovery and development efforts with MIN-101 and MIN-117 will be
successful; our ability to achieve the results contemplated by our
co-development agreements; management’s ability to successfully achieve its
goals; our ability to raise additional capital to fund our operations on terms
acceptable to us; and general economic conditions. These and other potential
risks and uncertainties that could cause actual results to differ from the
results predicted are more fully detailed under the caption “Risk Factors” in
our filings with the Securities and Exchange Commission, including our
Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, filed with
the Securities and Exchange Commission on August 4, 2016. Copies of reports
filed with the SEC are posted on our website at www.minervaneurosciences.com.
The forward-looking statements in this press release are based on information
available to us as of the date hereof, and we disclaim any obligation to update
any forward-looking statements, except as required by law.

Contact:

William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.